Anna Phil
Director/Board Member chez JASPER THERAPEUTICS, INC.
Fortune : 69 730 $ au 31/03/2024
Profil
Anna French Phil is currently working as a Director at Cardialen, Inc., WindMIL Therapeutics, Inc., Auron Therapeutics, Inc., Jasper Tx Corp., Umoja Biopharma, Inc., Jasper Therapeutics, Inc., Paros Bio, Inc., and Qiming US Ventures Management, LLC.
Dr. Phil has a graduate degree from the University of Oxford and an undergraduate degree from the University of Bristol.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/10/2023 | 2 375 ( 0,02% ) | 69 730 $ | 31/03/2024 |
Postes actifs de Anna Phil
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Director/Board Member | 24/09/2019 |
Qiming US Ventures Management, LLC
 Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a Venture Capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Analyst | 01/01/2017 |
WindMIL Therapeutics, Inc.
 WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Director/Board Member | 01/06/2018 |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Director/Board Member | 01/08/2020 |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Director/Board Member | 01/01/2019 |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Director/Board Member | 01/12/2020 |
Cardialen, Inc.
 Cardialen, Inc. Medical SpecialtiesHealth Technology Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO. | Director/Board Member | - |
Paros Bio, Inc.
 Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Director/Board Member | - |
Formation de Anna Phil
| University of Oxford | Graduate Degree |
| University of Bristol | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| Entreprise privées | 7 |
|---|---|
Cardialen, Inc.
Cardialen, Inc. Medical SpecialtiesHealth Technology Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO. | Health Technology |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Health Technology |
Qiming US Ventures Management, LLC
Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a Venture Capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | Health Technology |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | Health Technology |
